SecBot SecBot
EFFECT ·Filed Jun 17, 2026

VALN

Valneva SE
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC9999999995-26-002019
IPO/offering going effective
Actionable Insight • Neutral

Monitor for any subsequent prospectus supplement or takedown announcement that would indicate an actual offering and its size. Until then, the shelf creates theoretical overhang but no immediate dilution. A near-term secondary could pressure VALN shares; a lack of activity would be neutral.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.35
T+0 close · Jun 17, 2026 · via day close
Latest settled
+24.49%
T+60 · $6.66
Vs SPY
+21.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $5.35entry
  2. T+1 · 5mo ago +0.56%α −0.22% · $5.38
  3. T+5 · 5mo ago −2.24%α −1.20% · $5.23
  4. T+20 · 4mo ago −5.05%α −6.36% · $5.08
  5. T+60 · 2mo ago +24.49%α +21.34% · $6.66
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Valneva SE's SEC registration statement (F-3, File No. 333-296504) became effective as of June 16, 2026, allowing the company to offer and sell securities (likely common shares or other securities) from time to time. This does not indicate an immediate offering but creates potential dilution overhang that may weigh on the stock until any specific offering is announced and/or completed.

Key Facts

  • Form EFFECT for F-3 registration statement filed by Valneva SE
  • Effectiveness date: June 16, 2026
  • SEC File No. 333-296504
  • Shelf registration, no specific offering size, pricing, or terms disclosed

Financial Impact

Undisclosed shelf registration; no offering amount or terms provided. Potential future dilution is indeterminate without further disclosure.

dilutionshare count

Risk Factors

  • Potential future dilution if securities are offered under the shelf
  • No specific deal catalyst or timeline provided, uncertainty about capital raise plans

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002019
Document: 9999999995-26-002019-index.html9999999995-26-002019
Document: 9999999995-26-002019.txt9999999995-26-002019

US Market Status

Market Closed · Opens Wed (10h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 17, 2026